

Naftin[®] (naftifine) – First-time generic

- On June 3, 2019, Amneal launched a generic version of Sebela's <u>Naftin (naftifine)</u> 1% gel.
 - Tolmar received <u>FDA approval</u> of an <u>AB-rated</u> generic version of Naftin 1% gel on March 20, 2019. Launch plans for this generic product are pending.
- Naftin is approved for the topical treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms *Trichophyton rubrum*, *Trichophyton mentagrophytes*, *Trichophyton tonsurans*, *Epidermophyton floccosum*.
- Naftin is also available generically as a <u>1% cream</u> and <u>2% cream</u>, and as brand <u>2% gel</u>.
 - The 1% and 2% creams are approved for the treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organism *Trichophyton rubrum*.
 - Naftin 2% gel is indicated for the treatment of interdigital tinea pedis caused by the organisms *Trichophyton rubrum*, *Trichophyton mentagrophytes*, and *Epidermophyton floccosum*.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.